AFRICAN AMERICAN ANTIPLATELET STROKE PREVENTION STUDY

非裔美国人抗血小板中风预防研究

• 批准号: 6869987
• 负责人: PHILIP B GORELICK
• 金额: $ 145.84万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-07-01 至 2005-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6869987
• 关键词: African American; aspirin; cardiovascular disorder prevention; clinical research; clinical trials; fibrinolytic agents; human middle age (35-64); human old age (65+); human subject; human therapy evaluation; longitudinal human study; myocardial infarction; platelet aggregation inhibitors; relapse /recurrence; stroke; young adult human (21-34)

This is an application for the continuation of the ongoing trial "African-American Antiplatelet Stroke Prevention Trial (AAASP). This is a multicenter, randomized double blind clinical trial comparing ticlopidine (500 mg/day) with aspirin (650 mg/day). The purpose is to test the efficacy of the two treatments in preventing recurrent stroke, vascular death and myocardial infarction. Patients are enrolled no more than 90 days after incident cerebral infarction and are followed for 2 years. The investigators have already recruited 1400 of the needed 1800 subjects. Dr. Gorelick and colleagues have demonstrated their ability to conduct a trial of this magnitude having overcome initial difficulties in recruitment, which require the expansion to sites outside the Chicago area. They have currently completed two-thirds of the projected enrollment and should be able to continue to administer this trial competently to its conclusion.

这是一份继续进行中的审判的申请 非裔美国人抗血小板卒中预防试验(AAASP)。 多中心随机双盲临床试验比较噻氯匹定(500 阿司匹林650毫克/天)。这样做的目的是为了测试 预防再发卒中、血管性死亡和心肌梗死的两种疗法 脑梗塞。患者在脑部事件发生后不超过90天入选 并随访2年。调查人员已经 在所需的1800名受试者中招募了1400人。 戈雷里克博士和他的同事已经证明了他们有能力进行一项试验 克服了招聘初期的困难，取得了如此重大的成就 需要扩展到芝加哥地区以外的地点。他们目前有 已完成预计招生人数的三分之二，应该能够继续 有能力地管理这场审判直到它的结束。